Article Text
PDFViewpoint
Commentary
Ethics of paediatric end-of-life decision making and consent for publication
Statistics from Altmetric.com
Footnotes
-
Competing interests None.
-
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Editorial
- Viewpoint
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Outcome of goal-directed non-invasive ventilation and mechanical insufflation/exsufflation in spinal muscular atrophy type I
- Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1–3
- Nusinersen for SMA: expanded access programme
- British Thoracic Society guideline for respiratory management of children with neuromuscular weakness
- Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review
- The best interests test at the end of life on PICU: a plea for a family centred approach
- Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)
- Infantile spinal muscular atrophy variant with congenital fractures in a female neonate: evidence for autosomal recessive inheritance
- Spinal muscular atrophy: untangling the knot?
- Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4